Home > News > Starpharma Pooled Development - half year report and accounts
February 25th, 2004
Starpharma Pooled Development - half year report and accounts
The results for the half year include a 42% reduction in the operating loss of the economic entity during the period, compared with the corresponding period of the previous year. Whilst part of this improvement has resulted from the successful conversion of the former controlled entity Dendritic Nanotechnologies Ltd to a US incorporated associated entity (Dendritic Nanotechnologies, Inc), two thirds of the savings are attributable to reductions in expenditure by the Australian group, as set out in the report.
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014
Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 4, 2014 January 15th, 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress January 7th, 2014